Related Experiment Video
Updated: Dec 25, 2025
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
The CRISP(Y) Future of Pediatric Soft Tissue Sarcomas
Silvia Pomella1, Rossella Rota1
1Department of Oncohematology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Abstract:
The RNA-guided clustered regularly interspaced palindromic repeats (CRISPR)/associated nuclease 9 (Cas9)-based genome editing technology has increasingly become a recognized method for translational research. In oncology, the ease and versatility of CRISPR/Cas9 has made it possible to obtain many results in the identification of new target genes and in unravel mechanisms of resistance to therapy. The majority of the studies have been made on adult tumors so far. In this mini review we present an overview on the major aspects of CRISPR/Cas9 technology with a focus on a group of rare pediatric malignancies, soft tissue sarcomas, on which this approach is having promising results.
Insights
The CRISPR/Cas9 genome editing tool shows promise in oncology research, particularly for rare pediatric soft tissue sarcomas. This technology aids in identifying new cancer targets and understanding therapy resistance mechanisms.
Area of Science:
- Biotechnology
- Genomics
- Oncology
Background:
- CRISPR/Cas9 is a versatile genome editing technology increasingly used in translational research.
- Its application in oncology has facilitated the identification of novel therapeutic targets and resistance mechanisms.
- Most current research focuses on adult tumors, with limited exploration in pediatric malignancies.
Purpose of the Study:
- To provide an overview of CRISPR/Cas9 technology.
- To highlight its application in rare pediatric malignancies, specifically soft tissue sarcomas.
- To discuss the promising results of CRISPR/Cas9 in this area.
Main Methods:
- Review of existing literature on CRISPR/Cas9 technology in oncology.
- Focus on studies involving pediatric soft tissue sarcomas.
- Analysis of CRISPR/Cas9's role in target identification and resistance mechanisms.
Main Results:
- CRISPR/Cas9 enables efficient gene identification and functional studies in cancer research.
- The technology is demonstrating significant potential in understanding and treating soft tissue sarcomas.
- Early findings suggest CRISPR/Cas9 can unravel complex resistance pathways in pediatric cancers.
Conclusions:
- CRISPR/Cas9 is a powerful tool for advancing oncology research, especially in rare pediatric cancers.
- Its application in soft tissue sarcomas offers new avenues for therapeutic development.
- Further research is warranted to fully leverage CRISPR/Cas9 for pediatric cancer treatment.
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...